Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884
Debt
Debt-to-Equity RatioN/A
Current Ratio9.36
Quick Ratio9.36
Price-To-Earnings
Trailing P/E Ratio-11.40
Forward P/E Ratio-11.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales1,044.26
Cash FlowN/A
Price / CashN/A
Book Value$3.77 per share
Price / Book5.38
Profitability
EPS (Most Recent Fiscal Year)($1.78)
Net Income$-25,490,000.00
Net Margins-9,594.83%
Return on Equity-45.67%
Return on Assets-42.58%
Miscellaneous
Employees125
Outstanding Shares17,490,000
Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How will Cellular Biomedicine Group's stock buyback program work?
Cellular Biomedicine Group declared that its Board of Directors has approved a stock repurchase plan on Sunday, June 4th 2017, which permits the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.05. The biotechnology company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.10 million. Cellular Biomedicine Group had a negative return on equity of 45.67% and a negative net margin of 9,594.83%. View Cellular Biomedicine Group's Earnings History.
When is Cellular Biomedicine Group's next earnings date?
What price target have analysts set for CBMG?
2 Wall Street analysts have issued 12 month price objectives for Cellular Biomedicine Group's stock. Their predictions range from $18.00 to $32.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $25.00 in the next year. View Analyst Ratings for Cellular Biomedicine Group.
What are Wall Street analysts saying about Cellular Biomedicine Group stock?
Here are some recent quotes from research analysts about Cellular Biomedicine Group stock:
- 1. According to Zacks Investment Research, "Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California. " (6/21/2018)
- 2. Maxim Group analysts commented, "As Gilead pays $12 Billion for the planned acquisiton of Kite (KITE – $178.28 – Hold) and the market shifts focus to the remaining stand-alone CAR-T players such as JUNO (JUNO – $43.67 – Buy) and bluebird (BLUE – $103.88 – Buy) we see an opportunity with CBMG in China." (8/29/2017)
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Iovance Biotherapeutics (IOVA), Adaptimmune Therapeutics (ADAP), DBV Technologies (DBVT), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Fate Therapeutics (FATE), Voyager Therapeutics (VYGR), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), Mesoblast (MESO), CASI Pharmaceuticals (CASI) and Nightstar Therapeutics (NITE).
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Mr. Bizuo Liu, Chief Exec. Officer, Interim Chief Financial Officer and Director (Age 53)
- Dr. Yihong Yao Ph.D., BS, Chief Scientific Officer (Age 50)
- Mr. Andrew K. Chan J.D., MBA, Sr. VP of Legal & Corp. Devel. and Board Sec. (Age 60)
- Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & Intervention
- Dr. Wen Tao Liu Ph.D., Strategic Advisor and Director (Age 62)
Has Cellular Biomedicine Group been receiving favorable news coverage?
Media coverage about CBMG stock has been trending somewhat negative recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of -0.02 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.70 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Cellular Biomedicine Group's major shareholders?
Cellular Biomedicine Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.22%) and Tibra Equities Europe Ltd (0.16%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.
Which institutional investors are buying Cellular Biomedicine Group stock?
CBMG stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd and Northern Trust Corp. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.
How do I buy shares of Cellular Biomedicine Group?
Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of CBMG stock can currently be purchased for approximately $20.30.
How big of a company is Cellular Biomedicine Group?
Cellular Biomedicine Group has a market capitalization of $314.79 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.
How can I contact Cellular Biomedicine Group?
Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]
MarketBeat Community Rating for Cellular Biomedicine Group (CBMG)
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
